Trials / Completed
CompletedNCT03940742
A Study of Tirzepatide in Participants With Impaired Liver Function
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
Timeline
- Start date
- 2019-07-22
- Primary completion
- 2020-09-22
- Completion
- 2020-09-22
- First posted
- 2019-05-07
- Last updated
- 2023-03-24
- Results posted
- 2023-03-24
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03940742. Inclusion in this directory is not an endorsement.